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OBJECTIVE—In metazoans, target of rapamycin complex 1
(TORC1) plays the key role in nutrient- and hormone-dependent
control of metabolism. However, the role of TORC1 in regulation
of triglyceride storage and metabolism remains largely unknown.
RESEARCH DESIGN AND METHODS—In this study, we
analyzed the effect of activation and inhibition of the mammalian
TORC1 (mTORC1) signaling pathway on the expression of adi-
pose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL),
lipolysis, lipogenesis, and lipid storage in different mammalian
cells.
RESULTS—Activation of mTORC1 signaling in 3T3-L1 adipo-
cytes by ectopic expression of Rheb inhibits expression of ATGL
and HSL at the level of transcription, suppresses lipolysis,
increases de novo lipogenesis, and promotes intracellular accu-
mulation of triglycerides. Inhibition of mTORC1 signaling by
rapamycin or by knockdown of raptor stimulates lipolysis pri-
marily via activation of ATGL expression. Analogous results have
been obtained in C2C12 myoblasts and mouse embryonic ﬁbro-
blasts with genetic ablation of tuberous sclerosis 2 (TSC2) gene.
Overexpression of ATGL in these cells antagonized the lipogenic
effect of TSC2 knockout.
CONCLUSIONS—Our ﬁndings demonstrate that mTORC1 pro-
motes fat storage in mammalian cells by suppression of lipolysis
and stimulation of de novo lipogenesis. Diabetes 59:775–781,
2010
T
arget of rapamycin (TOR; mTOR in mammalian
cells) is an evolutionarily conserved serine/thre-
onine protein kinase that is distributed between
the two functionally distinct protein complexes,
TORC1 and TORC2 (1). mTORC1, which is composed of
mTOR, raptor, mLST8, and PRAS40, represents the central
sensor of energy- and hormone-dependent metabolic reg-
ulation in metazoans (2,3). Activity of mTORC1 is con-
trolled by the low-molecular-weight GTPase Rheb and
GTPase-activating protein complex, which consists of two
subunits: tuberous sclerosis 1 (TSC1) and TSC2 (3).
It is believed that activation of mTORC1 promotes ana-
bolic processes, such as protein biosynthesis, and inhibits
the ultimate catabolic process, autophagy. On the contrary,
lack of nutrients/energy rapidly suppresses mTORC1 and
mTORC1-controlled anabolic processes and activates au-
tophagy (2,3).
Autophagy may represent the last line of defense against
starvation (2,4). At the same time, mammalian organisms
usually accumulate signiﬁcant (in the case of humans,
often, excessive) energy stores that eliminate the need for
autophagy as a source of energy under non–life-threaten-
ing conditions. Therefore, we have hypothesized that prior
to activation of autophagy, inhibition of the mTORC1
pathway should activate less traumatic catabolic pro-
cesses that speciﬁcally serve to generate energy for vitally
important cell functions. By the same token, activation of
the TSC-mTORC1 pathway may facilitate energy storage
when nutrients are unlimited. As in eukaryotes, energy is
stored primarily in the form of fat, we decided to study the
effect of the mTORC1 pathway on the central energy-
generating process, lipolysis.
Our results strongly suggest that mTORC1, indeed,
inhibits lipolysis and stimulates lipogenesis in adipocytes
and other mammalian cells. We believe that our results are
consistent with previously published data. Thus, in mice,
genetic ablation of the mTORC1 substrate, S6K1, produces
lean phenotype with elevated levels of free fatty acids in
the blood under high-fat diet, suggesting that S6K1 may
have an antilipolytic effect (5,6). On the contrary, knock-
down of 4E-BP1 and 4E-BP2 leads to increased adiposity
and reduced lipolysis (7).
In humans, hyperactivation of mTORC1 signaling in
patients with tuberous sclerosis often leads to the devel-
opment of hamartomas of the kidneys called angiomyoli-
pomas (8). From the pathophysiological standpoint, the
most essential element of angiomyolipomas is fat, suggest-
ing that hyperactivation of the mTORC1-mediated path-
way may contribute to accumulation of fat in vivo. In
addition, a recent study has demonstrated that the major-
ity of tuberous sclerosis patients have foci of fat in the
myocardium that are readily detectable by computed
tomography (9). These authors have concluded that such
fatty foci represent an essential characteristic of tuberous
sclerosis (9). Moreover, it is well known that the use of
the mTORC1 inhibitor, rapamycin, in clinical practice (to
prevent organ rejection in transplant patients, or for other
purposes) often results in dyslipidemia, which is currently
considered a prominent side effect of the drug (10,11). We
believe that our results may shed light on the molecular
mechanism of all these phenomena.
Furthermore, the regulatory link between mTORC1 and
lipolysis is evolutionarily conserved. Thus, in Drosophila,
overexpression of dTOR increases fat content (12),
whereas hypomorphic mutation of dTOR has the opposite
effect (13). In fact, inhibition of dTOR signaling increases
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represents an analog of the mammalian enzyme that has
several names (desnutrin, PNPLA2, TTS2.2, iPLA2), but
we will refer to it as ATGL for adipose triglyceride lipase.
ATGL is responsible for the bulk of triacylglycerol hydro-
lase activity in cells (14). Importantly, ATGL represents
the rate-limiting lipolytic enzyme in mammals (15–20),
ﬂies (21), and yeast (22). Furthermore, ATGL controls the
size of lipid droplets in basal adipocytes (23). We show
here that the mTORC1-mediated pathway suppresses lipol-
ysis and promotes fat accumulation in mammalian cells
primarily by inhibiting transcription of ATGL.
RESEARCH DESIGN AND METHODS
Antibodies. Polyclonal antibodies against ATGL and hormone-sensitive
lipase (HSL) were gifts from Dr. A. Greenberg (Tufts University); against LPL,
a gift from Dr. S. Fried (Boston University School of Medicine); and against
Ap2, a gift from Dr. S. Farmer (Boston University School of Medicine). A
rabbit polyclonal antibody against cellugyrin was described previously (24).
Polyclonal anti–peroxisome proliferator–activated receptor- and C/EBP
were from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibodies
against perilipin, raptor, and all phospho-speciﬁc antibodies were from Cell
Signaling Technology (Beverly, MA). Monoclonal antibody against adiponec-
tin was from Abcam (Cambridge, MA). Monoclonal anti–HA tag antibody was
from Covance (Berkeley, CA).
Cell culture. Preparation of 3T3-L1 and C2C12 cells stably expressing Rheb
was described previously (25,26). 3T3-L1 preadipocytes were cultured, differ-
entiated, and maintained as described previously (24). TSC2
/ mouse
embryonic ﬁbroblasts (MEFs) and littermate control wild-type MEFs (27) as
well as C2C12 myoblasts were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10 and 20% FBS, respectively, in 2
mmol/l L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin.
Animal experiments. All experiments with animals were performed under
the approved Institutional Animal Care and Use Committee protocol. Male
C57BL6 mice (10 weeks old; Charles River) were injected intraperitoneally
daily with 5 mg/kg rapamycin or vehicle (5 l DMSO in 500 l sterile PBS) for
2 days. Mice were killed 16 h after the last injection by CO2 inhalation followed
by cervical dislocation; epididymal fat fads were isolated, cut into small
pieces, and incubated in DMEM with 2% fatty acid–free BSA at 37°C for 2 h.
Glycerol release in the media was assayed as described below. Fat pads were
homogenized in PBS with 1% Triton X-100 and standard inhibitors of proteases
and phosphatases, and protein concentration was measured. Tissue homoge-
nates were also analyzed for protein expression by Western blotting.
Transient transfections and reporter gene assays. Transient transfec-
tions with cDNA were performed using Lipofectamine 2000 (Invitrogen Life
Technologies, Grand Island, NY) according to the manufacturer’s instructions.
Brieﬂy, 50% conﬂuent MEFs were transfected with 500 ng of luciferase and
100 ng of enhanced green ﬂuorescent protein (EGFP) cDNA in a 6-well plate
format. All experiments were performed in triplicate. After 48 h of transfec-
tion, cells were harvested in Reporter Lysis Buffer (Promega). Luciferase
activity was determined in whole-cell lysates using the Promega luciferase
assay kit and expressed as relative light units. Expression of EGFP was
measured ﬂuorometrically. Fireﬂy luciferase was normalized by EGFP ﬂuo-
rescence to correct for transfection efﬁciency.
Small interfering RNA (siRNA) against the sequence ATTACATTCACA
GACTCGGGC of mouse raptor and scrambled siRNA were obtained from
Integrated DNA Technologies (Coralville, IA). Transfection of siRNAs was
performed with the help of the DeliverX Plus delivery kit (Panomics)
according to instructions of the manufacturer.
RNA extraction and quantitative PCR. Total RNA was extracted using
TRIzol reagent (Invitrogen Life Technologies) and remaining DNA was
removed with DNase using DNA-free kit (Ambion). Reverse transcription of 1
g of total RNA was performed with random primers using ABI High-Capacity
cDNA Reverse Transcription Kits. cDNA was diluted 1:10 (vol/vol) with water
treated with diethyl pyrocarbonate. TaqMan reaction was carried out in a
384-well plate format in total volume of 20 l, containing 9 l diluted cDNA,
10 l2  TaqMan Universal PCR Master Mix, and 1 l probe. Gene expression
was determined by standard curve method and normalized either by glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), -actin, or 36B4 internal
control genes. Accuracy of RNA quantiﬁcation was optimized by DNase
treatment of the samples, no DNA, and no Taq controls. Primer and probe
sequences are available upon request.
Immunoﬂuorescence. MEFs were grown in a 60-mm dish and transfected
with HA-tagged ATGL expression construct. Cells were allowed to grow for 3
days after conﬂuence, then lifted up by trypsin for 10 min at 37°C, reseeded
onto Nunc LAB-TEK II 4-well chamber slides, and used for staining. Cells were
ﬁxed with 4% paraformaldehyde in PBS for 30 min. Fixed cells were washed
with PBS, permeabilized with 0.2% Triton X-100 for 5 min, blocked with PBS
with 5% donkey serum and 5% BSA, and stained with primary anti-HA
monoclonal antibody and cyanin 3–conjugated donkey anti-mouse IgG (Jack-
son ImmunoResearch). Each incubation with antibody lasted for 60 min at
room temperature and was followed by six quick washes with PBS. For
visualization of fat droplets, cells were incubated with Nile red (1:1,000 vol/vol
in 75% glycerol from 0.5 mg/ml stock in acetone) for another 30 min.
Vectashield with DAPI (Vector Laboratories, Burlingame, CA) was used for
mounting cells on slides that were then examined by ﬂuorescence microscopy
using Olympus IX70. Pictures were taken with the help of the Image-Pro 4.5
program.
Lipolysis assay. Differentiated 3T3-L1 adipocytes were incubated in Phenol
red–free DMEM with 2% fatty acid–free BSA for2ha t37°C in the presence or
in the absence of 10 mol/l isoproterenol. Glycerol content in the media was
measured colorimetrically at 540 nm using the Triglyceride (GPO) Reagent Set
(Pointe Scientiﬁc, Canton, MI) against a set of glycerol standards. Cells were
then washed with cold PBS and lysed in 1% Triton X-100 buffer, and the
protein concentration was determined and used to normalize glycerol release.
All the experiments were carried out in triplicates.
Lipogenesis assay. 3T3-L1 adipocytes were incubated with 1 Ci of
14C-
acetic acid (Perkin Elmer, Waltham, MA) for 24 h and total intracellular lipids
were extracted with hexane and 2-propanol (3:2 vol/vol) mixture. Solvents
were dried under nitrogen gas, and the pellet was resuspended in toluene.
Incorporation of [1,2-
14C]-acetic acid into lipid phase was assayed either by
scintillation counting or by separating on a thin-layer chromatography plate
(Whatman) using hexane/diethyl ester/acetic acid (70:30:1 vol/vol/vol) as
mobile phase after autoradiography. All the experiments were carried out in
triplicate and normalized by protein concentration in samples.
Measurement of triglycerides. Cells were lysed in PBS containing 1%
Nonidet P-40 and whole-cell lysates were analyzed for triglyceride content by
Triglyceride (GPO) Reagent Set according to the manufacturer’s instructions
against a set of triolein standards. Intracellular triglycerides were normalized
by protein concentrations.
Oil red O staining. Cells were washed with PBS, ﬁxed with 3.7% formalde-
hyde solution for 1 h, and stained with oil red O for 1 h using a 60:40 (vol/vol)
dilution in water of a 0.5% stock solution in isopropanol. Cells were then
washed twice with water and visualized under the microscope.
Triglyceride lipase assay. Cells were homogenized in HES buffer (250
mmol/l sucrose, 20 mmol/l HEPES, 1 mmol/l dithiothreitol, 1 mmol/l EDTA,
pH7.4), and cell lysates were centrifuged at 4°C for 20 min at 16000g.
Triglyceride lipase activity was measured in 100 g of supernatants by
addition of 100 l of substrate that was prepared by sonicating [1-
14C]-triolein
(70,000 cpm/reaction) in 100 mmol/l potassium phosphate, 2 mmol/l EDTA, pH
7.4, 1% BSA, 20 mol/l phosphatidyl inositol/phosphatidyl serine (1:1 wt/wt),
and 1 mmol/l dithiothreitol. Reaction mixtures were incubated at 37°C for 30
min, terminated by addition of 3.25 ml of methanol/chloroform/heptane
(10:9:7), and extracted with 1 ml of 0.1 mol/l potassium carbonate and 0.1
mol/l boric acid, pH 9.5. Liberated fatty acid was quantiﬁed in 700 lo ft h e
upper phase by liquid scintillation counting.
Oxygen consumption. The rate of change of dissolved O2 in medium
(bicarbonate-free DMEM with 10% FBS supplemented with 5 mmol/l glucose)
immediately surrounding adipocytes derived from 3T3-L1 adipocytes cultured
in custom 24-well plates (50,000 cells/well) was measured in a Seahorse
Bioscience instrument (model XF24). Genomic DNA was extracted from each
well using Pico Pure DNA extraction (Arcturus) and was quantiﬁed and used
to normalize the O2 consumption level/well.
Gel electrophoresis and Western blotting. Proteins were separated in
SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Milli-
pore, Bedford, MA) in 25 mmol/l Tris, 192 mmol/l glycine. After transfer, the
membrane was blocked with 10% nonfat milk in PBS with 0.5% Tween 20 for
2 h. The blots were probed overnight with speciﬁc primary antibodies at 4°C
followed by 1-h incubation at room temperature with horseradish peroxidase–
conjugated secondary antibodies (Sigma). Protein bands were detected with
the enhanced chemiluminescence substrate kit (PerkinElmer Life Sci-
ences, Boston, MA) using a Kodak Image Station 440CF (Eastman Kodak,
Rochester, NY).
Statistics. Student paired two-tailed t test was used to evaluate the statistical
signiﬁcance of the results.
RESULTS AND DISCUSSION
To determine the effect of mTORC1 on lipolysis, we have
created a line of 3T3-L1 adipocytes stably overexpressing
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after referred to as caRheb). As is described in our recent
study (25), expression of caRheb leads to the activation
of the mTORC1-mediated signaling pathway but appar-
ently does not change the level of cell differentiation as
indicated by similar levels of expression of peroxisome
proliferator–activated receptor-, C/EBP, and perilipin
(supplementary Fig. 1, available in an online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db09-
1602/DC1). Oxygen consumption of caRheb-expressing adi-
pocytes is also not different from control (supplementary
Fig. 2). However, the rate of basal and isoproterenol-
stimulated lipolysis in these cells is decreased correspond-
ingly threefold and ﬁvefold in comparison with empty
vector–infected cells (Fig. 1A).
It is now appreciated that lipolysis is a complicated
multistep process. The complete hydrolysis of triglycer-
ides to glycerol and free fatty acids is performed jointly by
triacylglyceride, diacylglyceride, and monoacylglyceride
lipases (14,28). Recently discovered enzyme ATGL (16–
18), together with its protein cofactor CGI-58 (29), seems
to be responsible for the bulk of triacylglycerol hydrolase
activity in various cells, although may not represent the
only triacylglycerol hydrolase in adipocytes (30). At the
same time, ATGL has low afﬁnity to diacylglycerides and
monoacylglycerides (14,28). The major diacylglyceride
lipase in adipocytes is HSL. Monoacylglyceride products
of HSL are hydrolyzed by constitutively active monoacyl-
glyceride lipase (14,28).
Using quantitative PCR, we found that the levels of
mRNA for ATGL and HSL were signiﬁcantly decreased in
Rheb-overexpressing adipocytes (Fig. 1B). Note that ATGL
mRNA was more abundant in 3T3-L1 adipocytes than HSL
mRNA, and the inhibitory effect of caRheb on the expres-
sion of ATGL mRNA was greater than its effect on HSL
mRNA. The protein levels of ATGL and HSL were also
decreased by 40 and 20% correspondingly (Fig. 1C). As
expected, reduced expression of ATGL was accompanied
by a comparable decrease in the total triacylglycerol
hydrolase activity in vitro (Fig. 1D).
Recent results suggest that mTORC1 may stimulate
lipogenesis in mammalian cells (rev. in 31). In agreement
with these data, we have also found that activation of
mTORC1 in adipocytes stimulates de novo lipogenesis
(Fig. 1E). Quantitative analysis of data shown in Fig. 1A
and E demonstrates that mTORC1-mediated inhibition of
basal lipolysis (from 16.4 	 1.3 nm  mg
1  h
1 in empty
vector cells to 6.1 	 0.78 in caRheb cells) may contribute
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FIG. 1. mTORC1 promotes accumulation of triglycerides and downregulates expression of ATGL and HSL in 3T3–L1 adipocytes. A: Empty
vector–infected (EV) and caRheb 3T3–L1 adipocytes on day 7 of differentiation were incubated in Phenol red–free DMEM with 2% fatty acid–free
BSA without (basal) or with (stimulated) 10 mol/l isoproterenol (Iso) for 2 h. Glycerol was measured in media aliquots in triplicate and
normalized by protein concentration in whole-cell lysates. Data are presented relative to nonstimulated EV cells and expressed as mean  SD.
B: Levels of ATGL, HSL, and CGI-58 mRNA in differentiated (day 7) EV (black bars)– and caRheb (white bars)–expressing 3T3–L1 adipocytes
were determined in triplicate by quantitative PCR and normalized by 36B4 mRNA levels. Data were expressed as mean  SD relative to the
expression levels in EV cells. C: 3T3–L1 adipocytes stably expressing Rheb or empty vector–transfected control adipocytes were homogenized,
and total lysates (50 g) were analyzed by Western blotting for ATGL, HSL, and perilipin. Irrelevant protein cellugyrin was used as loading
control. Right panel: Relative band intensities for ATGL and HSL were determined and normalized to cellugyrin in three independent
experiments using ImageJ software. Data were expressed as mean  SD relative to the expression levels in EV cells. D: Triglyceride (TG) lipase
activity in EV-infected or caRheb cells was measured in vitro in triplicate as described in the RESEARCH DESIGN AND METHODS section. E: 3T3–L1
adipocytes stably expressing Rheb or empty vector–transfected control adipocytes were treated with 1 Ci [1,2-
14C]-acetic acid for 24 h, and the
total lipids were extracted and separated on thin-layer chromatography in triplicate. Incorporation of
14C-labeled acetic acid into TGs was
determined by autoradiography (bottom panel). Top panel: Relative spot intensities for triglycerides were measured with the help of ImageJ
software and normalized to total protein. Data were expressed as mean  SD relative to the expression levels in EV cells. F: Accumulation of
intracellular triglycerides in empty vector–infected (EV) 3T3–L1 adipocytes and in cells stably expressing Rheb (caRheb) was measured on days
5 and 10 of differentiation. All panels:* P < 0.05; **P < 0.001.
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FIG. 2. Inhibition of mTORC1 signaling increases ATGL expression and lipolysis in adipocytes both in vitro and in vivo. A: 3T3–L1 adipocytes on
day 7 of differentiation were transfected with 30 nmol/l scrambled (sc) or siRNA directed against mouse Raptor (si-Raptor). After 48 h, cells were
homogenized and total lysates (50 g) were analyzed by Western blotting. Right panel: Relative band intensities for ATGL were determined and
normalized to cellugyrin. B: Levels of ATGL and HSL mRNA in sc (black bars) and si-Raptor cells (white bars) were determined by quantitative
PCR and normalized by GAPDH mRNA levels. Data were expressed as mean  SD relative to the expression levels in sc cells. **P < 0.001. C:
Glycerol release in the media was determined in sc and si-Raptor cells for 2 h. Data were expressed as mean  SD relative to nonstimulated
sc cells. D: 3T3–L1 adipocytes on day 7 of differentiation were incubated with 100 nmol/l rapamycin (Rap, white bars) or vehicle (Rap,
black bars) for 24 h. Levels of ATGL and HSL mRNA were determined by quantitative PCR and normalized by GAPDH mRNA levels.
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stimulation of de novo lipogenesis (from 0.82 	 0.12 nm 
mg
1  h
1 in empty vector cells to 1.93 	 0.38 in caRheb
cells), so, in this study, we decided to concentrate on the
former phenomenon.
In the next experiment, we knocked down the crucial
mTORC1 component, raptor, with the help of siRNA (Fig.
2A). Knockdown of raptor stimulated expression of ATGL
mRNA (Fig. 2B) and protein (Fig. 2A) but had virtually no
effect on the expression of HSL. Still, knockdown of raptor
caused signiﬁcant activation of both basal and isoproter-
enol-stimulated lipolysis (Fig. 2C). Treatment of 3T3-L1
adipocytes with the mTORC1 inhibitor, rapamycin, for
24 h had a similar positive effect on the expression of
ATGL (but not HSL) and on the rate of lipolysis (Fig.
2D–F). In agreement with in vitro results, administration
of rapamycin to mice in vivo also increased expression of
ATGL and ex vivo lipolysis in both white and brown
adipose tissue (Fig. 2G–I). Expression of HSL was not
affected by rapamycin treatment in vivo in a statistically
signiﬁcant fashion. Thus, activation of mTORC1 sup-
presses expression of both ATGL and, less so, HSL (Fig. 1B
and C), whereas inhibition of mTORC1 speciﬁcally in-
creases expression of ATGL and does not affect expres-
sion of HSL (Fig. 2). This suggests that mTORC1 may
regulate lipolysis primarily via ATGL.
Data were expressed as mean  SD relative to the expression levels in Rap cells. E: Whole-cell lysates of rapamycin-treated and not treated
3T3-L1 adipocytes were analyzed by Western blotting (50 g of total protein per lane). Right panel: Relative band intensities for ATGL were
determined and normalized to cellugyrin. F: Glycerol release in the media was determined in rapamycin-treated and not treated 3T3-L1
adipocytes for 2 h. Data are presented relative to nonstimulated cells not treated with rapamycin and expressed as mean  SD. G and H:
Epididymal fat pads (white adipose tissue, WAT) and interscapular brown adipose tissue (BAT) were isolated from mice injected with Rap or
vehicle for 2 days as described in the RESEARCH DESIGN AND METHODS section (n  4–10), and total homogenates were analyzed by Western blotting
(50 g of total protein per lane). Right panels: Intensities of ATGL and HSL bands were normalized by cellugyrin and expressed as mean  SD
relative to the vehicle-injected animals. I: Lipolysis was measured ex vivo using the epididymal fat pads from mice injected with vehicle solution
or rapamycin (Rap) for 2 h. All panels:* P < 0.05.
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FIG. 3. Genetic ablation of TSC2 promotes accumulation of triglycerides and decreases expression of ATGL in MEFs. A: Wild-type (TSC2
/) and
TSC2
/ MEFs were cultured in DMEM with 10% FBS for 8 days after conﬂuence with (Rap) or without (Rap) 100 nmol/l rapamycin. Cells
were then ﬁxed in formaldehyde and stained with oil red O. Representative photographs of the plates (top panels) and respective micrographs
(bottom panels) are shown. B: Western blot analysis of the ATGL protein in total cell lysates (50 g) prepared from TSC2
/ MEFs immediately
after conﬂuence (day 0) or after 8 days of conﬂuence (day 8) with or without 100 nmol/l rapamycin (Rap). Cellugyrin was used as loading control.
C: Whole-cell lysates were prepared from TSC2
/ and TSC2
/ MEFs immediately after conﬂuence (day 0) or after 8 days of conﬂuence (day 8)
and analyzed by Western blotting. D: Total lysates obtained from TSC2
/ MEFs immediately after conﬂuence (day 0) or after 8 days of
conﬂuence (day 8) were analyzed by Western blotting. 3T3-L1 preadipocytes (day 0) and differentiated 3T3-L1 adipocytes (day 8) served as
negative and positive controls, respectively. Cellugyrin was used as a loading control. E: ATGL mRNA was measured in TSC2
/ and TSC2
/
MEFs by quantitative PCR on the day of conﬂuence. Gene expression was normalized to GAPDH mRNA levels, and data were presented as mean 
SD relative to ATGL expression in TSC2
/ MEFs. F: TSC2
/ and TSC2
/ MEFs were transiently transfected with 2979/21 LUC ATGL
promoter construct together with EGFP. After 48 h, cells were washed three times in cold PBS and harvested in the reporter lysis buffer.
Luciferase activity in cell lysates was assayed as described in the RESEARCH DESIGN AND METHODS section and normalized by GFP ﬂuorescence. Data
are presented for triplicate samples as mean  SD. G: TSC2
/ and TSC2
/ MEFs were transfected with HA-tagged ATGL expression construct
and allowed to grow for 3 days after conﬂuence. Then, cells were replated onto 4-well chamber slides, ﬁxed with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100, and stained with primary anti-HA monoclonal antibody and cyanin 3–conjugated donkey anti-mouse IgG.
Lipid droplets were stained with Nile red. The ﬁgure shows quantiﬁcation of the number of fat droplets in 100 transfected (ATGL) and
nontransfected (ATGL) cells. All panels:* * P < 0.001. (A high-quality color representation of this ﬁgure is available in the online issue.)
P. CHAKRABARTI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 779Recently, Polak et al. (32) reported that knockout of
raptor in adipocytes decreased accumulation of triglycer-
ides in these cells both in vitro and in vivo, which is
consistent with our observations. Polak et al. (32) attrib-
uted this effect to elevated energy expenditure due to
mitochondrial uncoupling. Our results demonstrate that
mTORC1 may control the size of lipid stores in adipocytes
by adjusting the rates of lipogenesis and lipolysis. Further-
more, we suggest that inhibition of ATGL expression may
represent a major factor in mTORC1-induced triglyceride
accumulation.
To conﬁrm the link between the mTORC1-mediated
pathway and ATGL expression in a different cell type, we
used TSC2
/ MEFs that exhibit an elevated mTORC1
activity (27) together with wild-type (TSC2

/
) MEFs. As
shown in Fig. 3A, culturing for 8 days after conﬂuence
leads to a signiﬁcant accumulation of fat in TSC2
/ MEFs
in comparison with wild-type cells. Addition of rapamycin
to the media prevented fat accumulation. The levels of the
ATGL protein in TSC2
/ MEFs reversely correlated with
the level of fat accumulation and were signiﬁcantly de-
creased on day 8 after conﬂuence, whereas rapamycin
reversed the loss of ATGL (Fig. 3B).
Theoretically, it is possible that knockout of TSC2 in
MEFs activates the differentiation program in these cells
and converts them into adipocytes (33,34). Note, however,
that, unlike Zhang et al. (34), we cultured MEFs not in the
differentiation media but simply in DMEM. Under these
conditions, accumulation of fat in postconﬂuent TSC2
/
MEFs was not accompanied by any signiﬁcant increase in
adipose markers (Fig. 3C), which, in addition, were ex-
pressed in these cells at much lower levels than in
differentiated 3T3-L1 adipocytes (Fig. 3D). At the same
time, similar to the situation with Rheb-transfected 3T3-L1
adipocytes, genetic ablation of TSC2 signiﬁcantly de-
creased the level of ATGL mRNA in MEFs (Fig. 3E).
We then expressed the luciferase reporter construct
containing 3 kb mouse ATGL promoter (35) in wild-type
and TSC2
/ MEFs. As shown in Fig. 3F, the reporter
construct was expressed much more efﬁciently in wild-
type than in TSC2
/ MEFs. These results strongly suggest
that mTORC1 signaling is implemented in the transcrip-
tional control of ATGL expression.
To address the question of whether inhibition of ATGL
expression can account for mTORC1-mediated increase in
fat accumulation, we transiently expressed HA epitope–
tagged ATGL in wild-type and TSC2
/ MEFs (for cell
images, see supplementary Fig. 3). In agreement with data
shown in Fig. 3A, nontransfected TSC2
/ MEFs accumu-
late more fat than wild-type cells (Fig. 3G). Ectopic
expression of ATGL inhibited accumulation of triglycer-
ides in lipid droplets both in wild-type and TSC2
/ MEFs
(Fig. 3G; supplementary Fig. 3). We suggest, therefore, that
mTORC1-dependent inhibition of ATGL promotes lipid
accumulation in mammalian cells.
It has long been known that deposition of triglycerides
in skeletal muscle is reversely correlated with their insulin
sensitivity, although triglycerides per se may not affect
insulin signaling, and lipotoxicity is more likely attributed
to metabolic products of TGs (36–38). As skeletal mus-
cles have a relatively low, but still detectable level of
ATGL expression (35,39), we decided to determine
whether the mTORC1-mediated pathway controls accu-
mulation of triglycerides in myocytes as well. For that,
we used C2C12 myoblasts stably transfected with HA
epitope–tagged Rheb (26). As we have reported earlier
(26), insulin signaling in these cells is attenuated (see
also supplementary Fig. 4). In addition, Rheb-expressing
C2C12 myoblasts demonstrate increased lipid deposi-
tion (Fig. 4A and B) and decreased ATGL mRNA (Fig.
4C) and protein (Fig. 4D) in comparison with empty
vector–transfected cells.
Previous work has shown that suppression of ATGL in
3T3-L1 adipocytes with siRNA decreases both basal and
isoproterenol-stimulated lipolysis (39), and genetic ab-
lation of ATGL in mice leads to triglyceride deposition
in multiple tissues (19). In addition, mutations of ATGL
are associated with neutral lipid storage disease in
humans, an autosomal recessive disorder characterized
by accumulation of triglyceride droplets and myopathy
(40). These data as well as results described above suggest
that mTORC1-mediated downregulation of ATGL represents
an important factor in the overall control of lipid homeostasis
that may underlie the molecular nature of metabolic
disease.
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FIG. 4. Activation of mTORC1 promotes accumulation of triglycerides
and decreases expression of ATGL in C2C12 myoblasts. A: C2C12
myoblasts stably transfected with empty vector (C2C12) or wild-type
Rheb (C2C12-Rheb) were grown in DMEM supplemented with 20% FBS
for 8 days after conﬂuence. Cells were ﬁxed and stained with oil red O.
A representative photograph of the plates (top panel) and respective
microphotographs (bottom panel) are shown. B: Accumulation of
intracellular triglycerides in empty vector–infected C2C12 cells and in
cells stably expressing Rheb (Rheb) was measured on day 8 after
conﬂuence. *P < 0.05. C: Expression of ATGL was determined by
quantitative PCR, normalized to GAPDH, and expressed relative to the
expression levels in C2C12 myoblasts on days 0 and 8 after conﬂuence.
**P < 0.001. D: Levels of ATGL protein in whole-cell lysates were
determined by Western blotting on days 0 and 8 after conﬂuence (50 g
of total protein per lane). (A high-quality color representation of this
ﬁgure is available in the online issue.)
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